

**PARNAX LAB LIMITED**

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022. Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com

CIN:-L36912MH1982PLC027925

**AUDITED RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED 31.03.2015**

PART I											Rs. In Lacs
PART I	Particulars	Standalone					Consolidated				
		Audited	Unaudited	Audited	Audited	Audited	Audited	Unaudited	Audited	Audited	Audited
		Current Quarter Ended 31.03.2014	Previous Quarter ended 31.12.2014	Corresponding Quarter Ended 31.03.2014	Current Year Ended 31.03.2015	Previous Year 31.03.2014	Current Quarter Ended 31.03.2015	Previous Quarter ended 31.12.2014	Corresponding Quarter Ended 31.03.2014	Current Year Ended 31.03.2015	Previous Year 31.03.2014
<b>1</b>	<b>Income from operations</b>										
	(a) Net sales/income from operations (Net of excise duty)	387.78	478.76	455.44	1,585.55	1,794.15	2,598.15	2,865.74	2166.69	10,274.63	6,857.35
	(b) Other operating income	45.31	10.09	26.05	77.56	108.87	48.90	10.15	27.57	81.41	110.39
	<b>Total income from operations (net)</b>	<b>433.09</b>	<b>488.85</b>	<b>481.49</b>	<b>1,663.11</b>	<b>1,903.02</b>	<b>2,647.05</b>	<b>2,875.89</b>	<b>2,194.26</b>	<b>10,356.04</b>	<b>6,967.74</b>
<b>2</b>	<b>Expenses</b>										
	(a) Cost of materials consumed	142.74	234.96	264.73	722.45	1,185.52	1,690.24	1,717.37	1480.78	6,326.90	4,187.74
	(b) Purchases of stock-in-trade	99.53	31.24	0	153.52	48.19	99.53	31.24	0.00	153.52	48.19
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(6.63)	40.41	14.4	155.26	(101.80)	(47.73)	122.33	-82.41	210.72	(205.85)
	(d) Employee benefits expense	68.96	85.28	89.88	284.33	319.83	191.00	209.78	200.38	771.76	687.23
	(e) Depreciation and amortisation expense	21.03	18.23	18.82	79.85	80.49	94.05	87.34	53.74	299.32	210.28
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	84.89	85.97	76.14	301.67	355.05	395.14	427.67	416.65	1,609.91	1,311.67
	<b>Total expenses</b>	<b>410.52</b>	<b>496.09</b>	<b>463.97</b>	<b>1,697.08</b>	<b>1887.28</b>	<b>2422.23</b>	<b>2595.73</b>	<b>2069.14</b>	<b>9372.13</b>	<b>6239.26</b>
<b>3</b>	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items(1-2)</b>	<b>22.57</b>	<b>(7.24)</b>	<b>17.52</b>	<b>(33.97)</b>	<b>15.74</b>	<b>224.82</b>	<b>280.16</b>	<b>125.12</b>	<b>983.91</b>	<b>728.48</b>
<b>4</b>	Other Income	-	-	-	-	-	-	-	-	-	-
<b>5</b>	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)</b>	<b>22.57</b>	<b>(7.24)</b>	<b>17.52</b>	<b>(33.97)</b>	<b>15.74</b>	<b>224.82</b>	<b>280.16</b>	<b>125.12</b>	<b>983.91</b>	<b>728.48</b>
<b>6</b>	Finance costs	37.19	31.04	47.44	141.44	139.29	115.12	113.46	109.4	439.77	364.60
<b>7</b>	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)</b>	<b>(14.62)</b>	<b>(38.28)</b>	<b>(29.92)</b>	<b>(175.41)</b>	<b>(123.55)</b>	<b>109.70</b>	<b>166.70</b>	<b>15.72</b>	<b>544.14</b>	<b>363.88</b>
<b>8</b>	Exceptional Items	-	-	23.08	-	23.08	-	-	23.08	-	23.08
<b>9</b>	<b>Profit / (Loss) from ordinary activities before tax (7 ± 8)</b>	<b>(14.62)</b>	<b>(38.28)</b>	<b>(53.00)</b>	<b>(175.41)</b>	<b>(146.63)</b>	<b>109.70</b>	<b>166.70</b>	<b>(7.36)</b>	<b>544.14</b>	<b>340.80</b>
<b>10</b>	Tax Expense	-	-	-	(55.62)	(25.24)	-	-	-	118.43	91.43
<b>11</b>	<b>Net Profit / (Loss) from ordinary activities after tax (9 ± 10)</b>	<b>(14.62)</b>	<b>(38.28)</b>	<b>(53.00)</b>	<b>(119.79)</b>	<b>(121.39)</b>	<b>109.70</b>	<b>166.70</b>	<b>(7.36)</b>	<b>425.71</b>	<b>249.37</b>
<b>12</b>	Extraordinary items (net of tax expense Rs.____ Lakhs)	-	-	-	-	-	-	-	-	-	-
<b>13</b>	<b>Net Profit / (Loss) for the period (11 ± 12)</b>	<b>(14.62)</b>	<b>(38.28)</b>	<b>(53.00)</b>	<b>(119.79)</b>	<b>(121.39)</b>	<b>109.70</b>	<b>166.70</b>	<b>(7.36)</b>	<b>425.71</b>	<b>249.37</b>

14	Share of Profit / (loss) of associates*	-	-	-	-	-	-	-	-	-	-
15	Minority Interest *	-	-	-	-	-	(0.10)	0.41	0.09	1.09	0.74
16	<b>Net Profit / (Loss) after taxes, Minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *</b>	(14.62)	(38.28)	(53.00)	(119.79)	(121.39)	109.80	166.29	(7.45)	424.62	248.63
17	Paid-up equity share capital (Face Value of the share Rs. 10 )	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866	850.4866
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	652.70	652.70	-	-	-	2,513.04	1,238.83
19.i	<b>Earning per share (before extraordinary items) (of Rs. 10/-each) (not annualised)</b>										
	(a) Basic	(0.17)	(0.45)	(0.62)	(1.41)	(1.43)	1.29	1.96	(0.09)	4.99	2.92
	(b) Diluted	(0.17)	(0.45)	(0.62)	(1.41)	(1.43)	1.29	1.96	(0.09)	4.99	2.92
19.ii	<b>Earning per share (after extraordinary items) (of Rs. 10/-each) (not annualised)</b>										
	(a) Basic	(0.17)	(0.45)	(0.62)	(1.41)	(1.43)	1.29	1.96	(0.09)	4.99	2.92
	(b) Diluted	(0.17)	(0.45)	(0.62)	(1.41)	(1.43)	1.29	1.96	(0.09)	4.99	2.92

<b>PART II</b>						
		<b>Current Quarter Ended 31.03.2015</b>	<b>Previous Quarter ended 31.12.2014</b>	<b>Corresponding Quarter Ended 31.03.2014</b>	<b>Current Year Ended 31.03.2015</b>	<b>Previous Year 31.03.2014</b>
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>					
<b>1</b>	Public shareholding					
	- Number of shares	3,264,850	3,294,950	3,294,950	3,264,850	3,294,950
	- Percentage of shareholding	38.39	38.74	38.74	38.39	38.74
<b>2</b>	Promoter and Promoter Group Shareholding **					
	a) Pledged / Encumbered					
	- Number of shares	781,488	781,488	781,488	781,488	781,488
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	14.91	15.00	15.00	14.91	15.00
	- Percentage of shares (as a % of the total share capital of the company)	9.19	9.19	9.19	9.19	9.19
	b) Non - encumbered					
	- Number of shares	4,458,528	4,428,428	4,428,428	4,458,528	4,428,428
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	85.00	85.00	85.00	86.00	85.00
	- Percentage of shares (as a % of the total share capital of the company)	52.42	52.07	52.07	52.42	52.07

	<b>PARTICULARS</b>	
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
		<b>31.03.2015</b>
	Pending at the beginning of the quarter	-
	Received during the quarter	-
	Disposed of during the quarter	-
	Remaining unresolved at the end of the quarter	-

Notes:	
1	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 29, 2015.
2	The Company has opted to submit Standalone as well as Consolidated financial statements. The Consolidated financial results comprise the results of Parmax Lab Limited and One Subsidiary Company
3	Pursuant to approval of Registrar of Companies, Mumbai, the name of the Company is changed to Parmax Lab Ltd w.e.f April 2, 2012
4	Since there is no income, expenditure and net profit after tax from earlier activity, the figures provided above are from new line of business i.e. Pharmaceutical Activity.
5	The figures of the last quarter is balancing figures between audited figures in respect to full financial year upto March 2015 and the unaudited published year to date figures upto December 31, 2014 being the date of the end of third quarter of the financial year which were subject to limited review.
6	The Consolidated financial results are prepared in accordance with Accounting Standards (AS 21 and 23) notified by Companies Accounting Standards Rules, 2006
7	Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.
8	EPS for quarter ended is on non annualised basis.
9	The Company is dealing into one segment; Dealing in Pharmaceutical Formulations

Date: 29.05.2015

Place: Mumbai

For Parmax Lab Limited



*[Handwritten Signature]*

Whole  
Time Director

Audited Statement of Assets and Liabilities as at March 31, 2015			(Rs. In Lacs)		
			Standalone		
			Consolidated		
			Year Ended As At		
			Year Ended As At		
			31.03.2015	31.03.2014	
			31.03.2015	31.03.2014	
<b>A</b>	<b>EQUITY AND LIABILITIES</b>				
<b>1</b>	<b>Shareholders' funds</b>				
(a)	Share capital	850.49	850.49	850.49	850.49
(b)	Reserves and surplus	411.51	531.30	1,662.55	1,238.84
(c)	Money received against share warrants	-	-	-	-
	<b>Sub-total - Shareholders' funds</b>	<b>1,262.00</b>	<b>1,381.79</b>	<b>2,513.04</b>	<b>2,089.33</b>
<b>2</b>	<b>Share application money pending allotment</b>				
		-	-	-	-
<b>3</b>	<b>Minority interest*</b>				
		-	-	4.78	3.69
<b>4</b>	<b>Non-current liabilities</b>				
(a)	Long-term borrowings	1,537.83	1,341.99	2,563.95	2,028.06
(b)	Deferred tax liabilities (net)	-	-	85.60	119.01
(c)	Other long-term liabilities	-	-	-	-
(d)	Long-term provisions	-	-	13.98	9.31
	<b>Sub-total - Non-current liabilities</b>	<b>1,537.83</b>	<b>1,341.99</b>	<b>2,663.53</b>	<b>2,156.38</b>
<b>5</b>	<b>Current liabilities</b>				
(a)	Short-term borrowings	204.86	213.54	1,209.17	1,032.25
(b)	Trade Payables	205.97	464.61	273.95	2,239.20
(c)	Other current liabilities	297.95	264.64	805.83	698.64
(d)	Short-term provisions	7.86	13.14	159.41	119.18
	<b>Sub-total - Current liabilities</b>	<b>716.64</b>	<b>955.93</b>	<b>2,448.36</b>	<b>4,089.27</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>3,516.47</b>	<b>3,679.71</b>	<b>7,629.71</b>	<b>8,338.67</b>
<b>B</b>	<b>ASSETS</b>				
<b>1</b>	<b>Non-current assets</b>				
(a)	Fixed assets	728.04	799.72	3,705.19	3,625.03
(b)	Goodwill on consolidation *	-	-	-	-
(c)	Non-current investments	1,071.44	1,071.44	85.95	85.95
(d)	Deferred tax assets (net)	202.87	146.94	-	-
(e)	Long-term loans and advances	16.72	16.72	40.79	36.68
(f)	Other non-current asstes	0.53	1.19	0.53	1.19
	<b>Sub-total - Non-current Assets</b>	<b>2,019.60</b>	<b>2,036.01</b>	<b>3,832.46</b>	<b>3,748.85</b>
<b>2</b>	<b>Current assets</b>				
(a)	Current Investments	-	-	-	-
(b)	Inventories	143.43	388.08	703.19	1,583.28
(c)	Trade receivables	1,083.88	992.84	2,350.12	2,490.06
(d)	Cash and cash equivalents	37.13	20.48	235.90	90.81
(e)	Short-term loans and advances	232.43	242.30	508.04	425.67
(f)	Other current asstes	-	-	-	-
	<b>Sub-total - Current Assets</b>	<b>1,496.87</b>	<b>1,643.70</b>	<b>3,797.25</b>	<b>4,589.82</b>
	<b>TOTAL - ASSETS</b>	<b>3,516.47</b>	<b>3,679.71</b>	<b>7,629.71</b>	<b>8,338.67</b>

\*Applicable in the case of consolidated statement of assets and liabilities



■ TEL : 022 - 3001 5868  
■ FAX : 022 - 2405 7708  
■ E-Mail : info@naxparlab.com  
■ Visit us at: www.naxparlab.com  
■ CIN No. : L36912MH1982PLC027925

# Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,  
SIDN-CHUNABHATTI, MUMBAI - 400 022, INDIA.

29<sup>th</sup> May, 2015.

To,

DCS-CRD  
BSE Limited.  
Dalal Street,  
Fort,  
Mumbai - 400 001

**Sub.: Approval of Accounts for the year ended 31<sup>st</sup> March, 2015 pursuant to clause 20(b) of the listing agreement.**

**Ref: Parnax Lab Limited. Scrip Code. 506128.**

Dear Sir,

This is to inform you that in the meeting of Board of Directors held on Friday the May 29, 2015 the Board has approved accounts for the year ended 31<sup>st</sup> March, 2015 and also approved the following in pursuance of clause 20(b) of the Listing Agreement.

Sr. No.	Particulars	For the year ended 31 <sup>st</sup> March, 2015 (Rs.)	For the year ended 31 <sup>st</sup> March, 2014 (Rs.)
1.	Total Turnover	16,35,97,627	19,44,37,087
2.	Gross Profit/(Loss)	5,54,31,049	6,62,23,913
3.	Provision for Depreciation	79,84,775	80,48,853
4.	Provision for Taxation	0	0
5.	C/f. Profit/(Loss) of previous year	(1,05,35,603)	16,03,781
6.	Appropriations out of Total Profits	0	0



**Works :** Plot No. 120, Masat Ind. Estate, Dadra & Nagar Haveli, Silvassa-396230 (India)  
Plot No. 121 & 74, Masat Ind. Estate, Dadra & Nagar Haveli, Silvassa-396230 (India)  
Phone : 0260 - 2640644 / 2641066 • Fax : 0260-2840655 • E-mail : naxpar@gmail.com



- TEL : 022 - 3001 5888
- FAX : 022 - 2405 7708
- E-Mail : info@naxparlab.com
- Visit us at: www.naxparlab.com
- CIN No. : L36912MH1982PLC027925

# Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX,  
SION-CHUNABHATTI, MUMBAI - 400 022, INDIA.

7.	Provision for Dividend	0	0
8.	Balance C/f. to Balance Sheet	(2,25,14,963)	(1,05,35,603)

This is for your information & record.

Thanking you,

Yours truly,  
For Parnax Lab Limited



Name : PRAKASH M SHAH  
(Designation) Director  
Din No. 00440980